Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

COO vs JNJ

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
COO
The Cooper Companies, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$11.97B
5Y Perf.-22.9%
JNJ
Johnson & Johnson

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$541.31B
5Y Perf.+51.0%

COO vs JNJ — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
COO logoCOO
JNJ logoJNJ
IndustryMedical - Instruments & SuppliesDrug Manufacturers - General
Market Cap$11.97B$541.31B
Revenue (TTM)$4.15B$92.15B
Net Income (TTM)$401M$25.12B
Gross Margin64.2%68.1%
Operating Margin17.2%26.1%
Forward P/E13.2x19.4x
Total Debt$2.78B$36.63B
Cash & Equiv.$111M$24.11B

COO vs JNJLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

COO
JNJ
StockMay 20May 26Return
The Cooper Companie… (COO)10077.1-22.9%
Johnson & Johnson (JNJ)100151.0+51.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: COO vs JNJ

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JNJ leads in 5 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. The Cooper Companies, Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
COO
The Cooper Companies, Inc.
The Growth Play

COO is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 5.1%, EPS growth -4.6%, 3Y rev CAGR 7.3%
  • Lower volatility, beta 0.93, Low D/E 33.8%, current ratio 1.89x
  • 5.1% revenue growth vs JNJ's 4.3%
Best for: growth exposure and sleep-well-at-night
JNJ
Johnson & Johnson
The Income Pick

JNJ carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 36 yrs, beta 0.06, yield 2.2%
  • 136.2% 10Y total return vs COO's 59.8%
  • Beta 0.06, yield 2.2%, current ratio 1.11x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthCOO logoCOO5.1% revenue growth vs JNJ's 4.3%
ValueCOO logoCOOLower P/E (13.2x vs 19.4x)
Quality / MarginsJNJ logoJNJ27.3% margin vs COO's 9.7%
Stability / SafetyJNJ logoJNJBeta 0.06 vs COO's 0.93
DividendsJNJ logoJNJ2.2% yield; 36-year raise streak; the other pay no meaningful dividend
Momentum (1Y)JNJ logoJNJ+48.8% vs COO's -24.1%
Efficiency (ROA)JNJ logoJNJ13.0% ROA vs COO's 3.2%, ROIC 20.7% vs 4.8%

COO vs JNJ — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

COOThe Cooper Companies, Inc.
FY 2025
Coopervision Segment
67.0%$2.7B
Coopersurgical Segment
33.0%$1.3B
JNJJohnson & Johnson
FY 2024
Innovative Medicine
64.1%$57.0B
MedTech
35.9%$31.9B

COO vs JNJ — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJNJLAGGINGCOO

Income & Cash Flow (Last 12 Months)

JNJ leads this category, winning 6 of 6 comparable metrics.

JNJ is the larger business by revenue, generating $92.1B annually — 22.2x COO's $4.2B. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to COO's 9.7%.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
RevenueTrailing 12 months$4.2B$92.1B
EBITDAEarnings before interest/tax$1.0B$31.4B
Net IncomeAfter-tax profit$401M$25.1B
Free Cash FlowCash after capex$333M$19.1B
Gross MarginGross profit ÷ Revenue+64.2%+68.1%
Operating MarginEBIT ÷ Revenue+17.2%+26.1%
Net MarginNet income ÷ Revenue+9.7%+27.3%
FCF MarginFCF ÷ Revenue+8.0%+20.7%
Rev. Growth (YoY)Latest quarter vs prior year+6.2%+6.8%
EPS Growth (YoY)Latest quarter vs prior year+26.9%+91.0%
JNJ leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

COO leads this category, winning 5 of 6 comparable metrics.

At 32.7x trailing earnings, COO trades at a 16% valuation discount to JNJ's 38.8x P/E. On an enterprise value basis, COO's 13.2x EV/EBITDA is more attractive than JNJ's 18.8x.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
Market CapShares × price$12.0B$541.3B
Enterprise ValueMkt cap + debt − cash$14.6B$553.8B
Trailing P/EPrice ÷ TTM EPS32.68x38.79x
Forward P/EPrice ÷ next-FY EPS est.13.24x19.39x
PEG RatioP/E ÷ EPS growth rate34.49x
EV / EBITDAEnterprise value multiple13.24x18.78x
Price / SalesMarket cap ÷ Revenue2.93x6.09x
Price / BookPrice ÷ Book value/share1.48x7.63x
Price / FCFMarket cap ÷ FCF27.61x27.28x
COO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

JNJ leads this category, winning 5 of 8 comparable metrics.

JNJ delivers a 31.7% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $5 for COO. COO carries lower financial leverage with a 0.34x debt-to-equity ratio, signaling a more conservative balance sheet compared to JNJ's 0.51x.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
ROE (TTM)Return on equity+4.8%+31.7%
ROA (TTM)Return on assets+3.2%+13.0%
ROICReturn on invested capital+4.8%+20.7%
ROCEReturn on capital employed+6.1%+17.6%
Piotroski ScoreFundamental quality 0–955
Debt / EquityFinancial leverage0.34x0.51x
Net DebtTotal debt minus cash$2.7B$12.5B
Cash & Equiv.Liquid assets$111M$24.1B
Total DebtShort + long-term debt$2.8B$36.6B
Interest CoverageEBIT ÷ Interest expense6.40x48.23x
JNJ leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

JNJ leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in JNJ five years ago would be worth $14,803 today (with dividends reinvested), compared to $6,033 for COO. Over the past 12 months, JNJ leads with a +48.8% total return vs COO's -24.1%. The 3-year compound annual growth rate (CAGR) favors JNJ at 13.9% vs COO's -14.1% — a key indicator of consistent wealth creation.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
YTD ReturnYear-to-date-24.6%+9.0%
1-Year ReturnPast 12 months-24.1%+48.8%
3-Year ReturnCumulative with dividends-36.7%+47.6%
5-Year ReturnCumulative with dividends-39.7%+48.0%
10-Year ReturnCumulative with dividends+59.8%+136.2%
CAGR (3Y)Annualised 3-year return-14.1%+13.9%
JNJ leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

JNJ leads this category, winning 2 of 2 comparable metrics.

JNJ is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than COO's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JNJ currently trades 89.2% from its 52-week high vs COO's 68.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
Beta (5Y)Sensitivity to S&P 5000.93x0.06x
52-Week HighHighest price in past year$89.83$251.71
52-Week LowLowest price in past year$60.00$146.12
% of 52W HighCurrent price vs 52-week peak+68.0%+89.2%
RSI (14)Momentum oscillator 0–10025.038.3
Avg Volume (50D)Average daily shares traded2.0M7.0M
JNJ leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

JNJ leads this category, winning 1 of 1 comparable metric.

Wall Street rates COO as "Buy" and JNJ as "Buy". Consensus price targets imply 53.6% upside for COO (target: $94) vs 11.0% for JNJ (target: $249). JNJ is the only dividend payer here at 2.17% yield — a key consideration for income-focused portfolios.

MetricCOO logoCOOThe Cooper Compan…JNJ logoJNJJohnson & Johnson
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$93.86$249.27
# AnalystsCovering analysts2440
Dividend YieldAnnual dividend ÷ price+2.2%
Dividend StreakConsecutive years of raises036
Dividend / ShareAnnual DPS$4.87
Buyback YieldShare repurchases ÷ mkt cap+2.4%+0.4%
JNJ leads this category, winning 1 of 1 comparable metric.
Key Takeaway

JNJ leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). COO leads in 1 (Valuation Metrics).

Best OverallJohnson & Johnson (JNJ)Leads 5 of 6 categories
Loading custom metrics...

COO vs JNJ: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is COO or JNJ a better buy right now?

For growth investors, The Cooper Companies, Inc.

(COO) is the stronger pick with 5. 1% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). The Cooper Companies, Inc. (COO) offers the better valuation at 32. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate The Cooper Companies, Inc. (COO) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — COO or JNJ?

On trailing P/E, The Cooper Companies, Inc.

(COO) is the cheapest at 32. 7x versus Johnson & Johnson at 38. 8x. On forward P/E, The Cooper Companies, Inc. is actually cheaper at 13. 2x.

03

Which is the better long-term investment — COO or JNJ?

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.

0%, compared to -39. 7% for The Cooper Companies, Inc. (COO). Over 10 years, the gap is even starker: JNJ returned +136. 2% versus COO's +59. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — COO or JNJ?

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus The Cooper Companies, Inc. 's 0. 93β — meaning COO is approximately 1534% more volatile than JNJ relative to the S&P 500. On balance sheet safety, The Cooper Companies, Inc. (COO) carries a lower debt/equity ratio of 34% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

05

Which is growing faster — COO or JNJ?

By revenue growth (latest reported year), The Cooper Companies, Inc.

(COO) is pulling ahead at 5. 1% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: The Cooper Companies, Inc. grew EPS -4. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, COO leads at 7. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — COO or JNJ?

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus 9. 2% for The Cooper Companies, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 16. 7% for COO. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is COO or JNJ more undervalued right now?

On forward earnings alone, The Cooper Companies, Inc.

(COO) trades at 13. 2x forward P/E versus 19. 4x for Johnson & Johnson — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COO: 53. 6% to $93. 86.

08

Which pays a better dividend — COO or JNJ?

In this comparison, JNJ (2.

2% yield) pays a dividend. COO does not pay a meaningful dividend and should not be held primarily for income.

09

Is COO or JNJ better for a retirement portfolio?

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, COO: +59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between COO and JNJ?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ pays a dividend while COO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

COO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

JNJ

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform COO and JNJ on the metrics below

Revenue Growth>
%
(COO: 6.2% · JNJ: 6.8%)
Net Margin>
%
(COO: 9.7% · JNJ: 27.3%)
P/E Ratio<
x
(COO: 32.7x · JNJ: 38.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.